DFTX shares stable as company confirms top-line results for DT120 ODT in generalized anxiety disorder trial by August 10, 2026.
Definium Therapeutics announced it has secured cash reserves sufficient to fund operations through 2030. The biotech firm expects to release top-line data from its Phase III Voyage study of DT120 ODT in generalized anxiety disorder during the week of August 10, 2026.
The trial targets a key milestone for DFTX, which previously reported mixed Phase II results. Analysts had anticipated data disclosure in mid-2026, aligning with management’s timeline. DT120 ODT remains the company’s lead candidate in a competitive anxiety disorder market.
Shares showed minimal movement following the update, reflecting investor focus on upcoming clinical results rather than financial runway extensions.